Collectively, these data suggest that blockade of TGFβ signalling activity could potentially promote efficient eradication of residual CML stem cells, a notion that is also supported the finding that Bcr-Abl enhances TGFβ signalling activity in CML cells [19]. Here, TGFB1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.